NCT00511862

TheraSphere for the Treatment of Liver Metastases

TheraSphere for the Treatment of Liver Metastases: An Open Label Trial of TheraSphere in Patients With Liver Metastases From Primary Colorectal Cancer, Neuroendocrine Cancer or Non-colorectal/Non-neuroendocrine Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 151 (actual)
• Sponsor: Boston Scientific Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate Liver Progression Free Survival (PFS) and safety of TheraSphere treatment at doses of 120 Gy +/1 10% in patients at least 18 years of age diagnosed with metastatic disease to the liver that cannot be treated or is progressing following treatment with systemic or other liver-directed therapies.

Conditions

• Colorectal Cancer
• Carcinoma, Neuroendocrine
• Neoplasm Metastasis

Interventions

Type	Name	Description
DEVICE	Yttrium 90 glass microspheres	120 Gy unilobar or bilobar infusion with the second infusion occurring 3-7 weeks following treatment of the first lobe

Timeline

• Start date: 2007-01-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2007-08-06
• Last updated: 2021-05-13
• Results posted: 2014-05-23

Locations

5 sites across 1 country: United States